Innovative Therapeutic Approaches Based on Nanotechnology for the Treatment and Management of Tuberculosis

References

• Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol. 2009;27:393–422.
   PubMed Web of Science ®Google Scholar
• Stewart GR, Robertson BD, Young DB. Tuberculosis: a problem with persistence. Nat Rev Microbiol. 2003;1(2):97–105.
   PubMed Web of Science ®Google Scholar
• World Heath Organization. Rapid Communication: Key Changes to the Treatment of Drug-Resistant Tuberculosis. World Heath Organization; 2022.
   Google Scholar
• WHO G. Global tuberculosis report 2020. Glob Tuberc Rep. 2020;2020:S7–S12.
   Google Scholar
• World Heath Organization. WHO Declares Tuberculosis a Global Emergency. World Heath Organization; 1993:0303–8408.
   Google Scholar
• Debjit B, Chandira R, Jayakar B, Kumar KS. Recent trends of drug used treatment of tuberculosis. J Chem Pharm Res. 2009;1(1):113–133.
   Google Scholar
• Greenblatt DJ. Elimination half-life of drugs: value and limitations. Annu Rev Med. 1985;36(1):421–427.
   PubMedGoogle Scholar
• Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA. 2005;293(22):2767–2775.
   PubMed Web of Science ®Google Scholar
• Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis. 2008;21(6):587–595.
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Plorde JJ, Martin TR. Clinical application of the Mycobacterium tuberculosis direct test: case report, literature review, and proposed clinical algorithm. Chest. 1998;114(1):317–323.
   PubMed Web of Science ®Google Scholar
• Griffiths G, Nyström B, Sable SB, Khuller GK. Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol. 2010;8(11):827–834.
   PubMed Web of Science ®Google Scholar
• Nasiruddin M, Neyaz M, Das S. Nanotechnology-based approach in tuberculosis treatment. Tuberc Res Treat. 2017;2017. doi:10.1155/2017/4920209
   PubMedGoogle Scholar
• Müller R, Mehnert W, Lucks J-S, Schwarz C, Zur Mühlen A. Solid lipid nanoparticles (SLN): an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm. 1995;41(1):62–69.
   Web of Science ®Google Scholar
• Sharma A K, Sharma R, Jhorar R, Kumar R. Nanomedicine in therapeutic intervention of tuberculosis meningitis. Curr Nanosci. 2015;11(1):15–22.
   Web of Science ®Google Scholar
• Kumar M, Jha A, Dr M, Mishra B. Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy. Expert Opin Drug Deliv. 2020;17(10):1459–1472.
   PubMed Web of Science ®Google Scholar
• Sarkar K, Kumar M, Jha A, Bharti K, Das M, Mishra B. Nanocarriers for tuberculosis therapy: design of safe and effective drug delivery strategies to overcome the therapeutic challenges. J Drug Deliv Sci Technol. 2021;67:102850.
   Web of Science ®Google Scholar
• Martini M, Besozzi G, Barberis I. The never-ending story of the fight against tuberculosis: from Koch’s bacillus to global control programs. J Prev Med Hyg. 2018;59(3):E241.
   PubMedGoogle Scholar
• Hadi SA, Brenner EP, Mani R, Palmer MV, Thacker T, Sreevatsan S. Genome Sequences of Mycobacterium tuberculosis Biovar bovis Strains Ravenel and 10-7428. Microbiol Resour Announc. 2021;10(24):e00411–e00421.
   PubMed Web of Science ®Google Scholar
• Robinson RK. Encyclopedia of Food Microbiology. Academic press; 2014.
   Google Scholar
• Moreno S. Tuberculosis multirresistente: epidemiología actual, esquemas terapéuticos, nuevos fármacos. Rev Esp Quimioter. 2016;29(1):35–38.
   PubMedGoogle Scholar
• Tuberculosis drugs and mechanisms of action. National Institute of Allergy and Infectious Diseases. https://www.niaid.nih.gov/diseases-conditions/tbdrugs. Accessed March 1, 2023.
   Google Scholar
• Ochi K. Phylogenetic analysis of mycolic acid-containing wall-chemotype IV actinomycetes and allied taxa by partial sequencing of ribosomal protein AT-L30. Int J Syst Evol Microbiol. 1995;45(4):653–660.
   Google Scholar
• Tsukamura M. A review of the methods of identification and differentiation of mycobacteria. Rev Infect Dis. 1981;3(5):841–861.
   PubMedGoogle Scholar
• Karami-Zarandi M, Bahador A, Gizaw Feysia S, et al. Identification of non-tuberculosis mycobacteria by line probe assay and determination of drug resistance patterns of isolates in Iranian patients. Arch Razi Inst. 2019;74(4):375–384.
   PubMedGoogle Scholar
• Tió-Coma M, Wijnands T, Pierneef L, et al. Detection of Mycobacterium leprae DNA in soil: multiple needles in the haystack. Sci Rep. 2019;9(1):1–7.
   PubMedGoogle Scholar
• Nardell EA. Transmission and institutional infection control of tuberculosis. Cold Spring Harb Perspect Med. 2016;6(2):a018192.
   Web of Science ®Google Scholar
• Chapter C. Transmission and Pathogenesis of Tuberculosis. US: Taylor and Francies; 2016.
   Google Scholar
• Fennelly KP. Particle sizes of infectious aerosols: implications for infection control. Lancet Respir Med. 2020;8(9):914–924.
   PubMed Web of Science ®Google Scholar
• Murray JF. The Normal Lung: the Basis for Diagnosis and Treatment of Pulmonary Disease. WB Saunders Company; 1986.
   Google Scholar
• Dannenberg A. Pathogenesis of Pulmonary Tuberculosis: Host-Parasite Interactions, Cellmediatedd Immunity, and Delayed-Type Hypersensitivity: Basic Principles. New York: Springer Verlag; 1994.
   Google Scholar
• Smith DW, Wiegeshaus EH. What animal models can teach us about the pathogenesis of tuberculosis in humans. Rev Infect Dis. 1989;11(Supplement_2):S385–S393.
   PubMedGoogle Scholar
• Reggiardo Z, Middlebrook G. Failure of passive serum transfer of immunity against aerogenic tuberculosis in rabbits. Proc Soc Exp Biol Med. 1974;145(1):173–175.
   PubMed Web of Science ®Google Scholar
• Canetti G. The Tubercle Bacillus in the Pulmonary Lesion of Man: Histobacteriology and its Bearing on the Therapy of Pulmonary Tuberculosis. Springer Publishing Company; 1955.
   Google Scholar
• Dannenberg JAM. Immune mechanisms in the pathogenesis of pulmonary tuberculosis. Rev Infect Dis. 1989;11(Supplement_2):S369–S378.
   PubMedGoogle Scholar
• Styblo K, Enarson DA. Epidemiology of Tuberculosis. Vol. 24. Royal Netherlands Tuberculosis Association The Hague; 1991.
   Google Scholar
• Bass JB, Farer LS, Hopewell PC, Jacobs RF, Snider DE. Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis. 1990;142(3):725–735.
   PubMedGoogle Scholar
• Susilawati TN, Larasati R. A recent update of the diagnostic methods for tuberculosis and their applicability in Indonesia: a narrative review. Med J Indones. 2019;28(3):284–291.
   Web of Science ®Google Scholar
• Cobat A, Orlova M, Barrera L, Schurr E. Host genomics and control of tuberculosis infection. Public Health Genomics. 2013;16(1–2):44–49.
   PubMed Web of Science ®Google Scholar
• Rate C. Tuberculosis in Alameda County; 2015.
   Google Scholar
• Yu WY, Wang YX, Mei JZ, Hu FX, Ji LC. Overview of Tuberculosis. In: Tuberculosis Control in Migrating Population. Springer; 2020:1–10.
   Google Scholar
• Gupta S, Kumar P, Gupta MK, Vyas SP. Colloidal carriers: a rising tool for therapy of tuberculosis. Crit Rev Ther Drug Carr Sys. 2012;29(4):299–353.
   PubMed Web of Science ®Google Scholar
• Wen Z, Li T, Zhu W, Chen W, Zhang H, Wang W. Effect of different interventions for latent tuberculosis infections in China: a model-based study. BMC Infect Dis. 2021;22:488.
   Web of Science ®Google Scholar
• Lee SH. Tuberculosis infection and latent tuberculosis. Tuberc Respir Dis. 2016;79(4):201–206.
   PubMedGoogle Scholar
• Esmail H, Barry III CE, Wilkinson RJ. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today. 2012;17(9–10):514–521.
   PubMed Web of Science ®Google Scholar
• Vonasek B, Ness T, Takwoingi Y, et al. Screening tests for active pulmonary tuberculosis in children. Cochrane Database Syst Rev. 2020;7. doi:10.1002/14651858.CD013693.pub2
   Google Scholar
• Kaur J, Gill G, Jeet K. Characterization and Biology of Nanomaterials for Drug Delivery. The Netherlands: Elsevier Amsterdam; 2019.
   Google Scholar
• Lee SH. Diagnosis and treatment of latent tuberculosis infection. Tuberc Respir Dis. 2015;78(2):56–63.
   PubMedGoogle Scholar
• Piccazzo R, Paparo F, Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. J Rheumatol Suppl. 2014;91:32–40.
   PubMedGoogle Scholar
• Kiazyk S, Ball T. Tuberculosis (TB): latent tuberculosis infection: an overview. Can Commun Dis Rep. 2017;43(3–4):62.
   PubMedGoogle Scholar
• Özüdogru E, Cakli H, Altuntas E, Gürbüz M. Effects of laryngeal tuberculosis on vocal fold functions: case report. Acta otorhinolaryngologica italica. 2005;25(6):374.
   PubMedGoogle Scholar
• Lee KM, Choe KH, Kim SJ. Clinical investigation of cavitary tuberculosis and tuberculous pneumonia. Korean J Intern Med. 2006;21(4):230.
   PubMedGoogle Scholar
• Ray S, Talukdar A, Kundu S, Khanra D, Sonthalia N. Diagnosis and management of miliary tuberculosis: current state and future perspectives. Ther Clin Risk Manag. 2013;9:9.
   PubMed Web of Science ®Google Scholar
• Jeon D. Tuberculous pleurisy: an update. Tuberc Respir Dis. 2014;76(4):153–159.
   PubMedGoogle Scholar
• Kelestimur F. The endocrinology of adrenal tuberculosis: the effects of tuberculosis on the hypothalamo-pituitary-adrenal axis and adrenocortical function. J Endocrinol Invest. 2004;27(4):380–386.
   PubMed Web of Science ®Google Scholar
• Benjelloun A, Darouassi Y, Zakaria Y, Bouchentouf R, Errami N. Lymph nodes tuberculosis: a retrospective study on clinical and therapeutic features. Pan Afr Med J. 2015;20:65.
   PubMedGoogle Scholar
• Johnson JL, Ellner JJ. Tuberculosis and atypical mycobacterial infections. In: Tropical Infectious Diseases. Elsevier Inc; 2006:394–427.
   Google Scholar
• Srivastava U, Almusa O, Tung KW, Heller MT. Tuberculous peritonitis. Radiol Case Report. 2014;9(3):971.
   PubMedGoogle Scholar
• Daher EDF, da Silva Junior GB, Barros EJG. Renal tuberculosis in the modern era. Am J Trop Med Hyg. 2013;88(1):54.
   PubMed Web of Science ®Google Scholar
• Chin JH. Tuberculous meningitis: diagnostic and therapeutic challenges. Neurol Clin Pract. 2014;4(3):199–205.
   PubMedGoogle Scholar
• Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation. 2005;112(23):3608–3616.
   PubMed Web of Science ®Google Scholar
• Silva DR, Muñoz-Torrico M, Duarte R, et al. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. Jornal Brasileiro de Pneumologia. 2018;44:145–152.
   PubMed Web of Science ®Google Scholar
• Narasimhan P, Wood J, MacIntyre CR, Mathai D. Risk factors for tuberculosis. Pulm Med. 2013;2013. doi:10.1155/2013/828939
   PubMedGoogle Scholar
• Hershkovitz I, Donoghue HD, Minnikin DE, et al. Tuberculosis origin: the Neolithic scenario. Tuberculosis. 2015;95:S122–S126.
   PubMed Web of Science ®Google Scholar
• Sakula A. Robert Koch: centenary of the discovery of the tubercle bacillus, 1882. Thorax. 1982;37(4):246–251.
   PubMed Web of Science ®Google Scholar
• Glaziou P, Floyd K, Raviglione MC. Global epidemiology of tuberculosis. Thieme Med Publish. 2018;34:271–285.
   Google Scholar
• Baranyai Z, Soria-Carrera H, Alleva M, et al. Nanotechnology-Based targeted drug delivery: an emerging tool to overcome tuberculosis. Adv Ther. 2021;4(1):2000113.
   Google Scholar
• Pardhi VP, Jain K. Impact of binary/ternary solid dispersion utilizing poloxamer 188 and TPGS to improve pharmaceutical attributes of bedaquiline fumarate. J Drug Deliv Sci Technol. 2021;62:102349.
   Web of Science ®Google Scholar
• Pai M, Kasaeva T, Swaminathan S. Covid-19’s devastating effect on tuberculosis care—a path to recovery. NEJM. 2022;386(16):1490–1493.
   PubMed Web of Science ®Google Scholar
• Chakaya J, Petersen E, Nantanda R, et al. The WHO global tuberculosis 2021 report–not so good news and turning the tide back to End TB. Int J Infect Dis. 2022;124:S26–S29.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report 2020: Executive Summary. World Health Organization; 2020.
   Google Scholar
• World Health Organization. Global Tuberculosis Report 2020. World Health Organization; 2021.
   Google Scholar
• Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol. 2020;128(6):1547–1567.
   PubMed Web of Science ®Google Scholar
• MacNeil A, Glaziou P, Sismanidis C, Date A, Maloney S, Floyd K. Global epidemiology of tuberculosis and progress toward meeting global targets—worldwide, 2018. MMWR. 2020;69(11):281.
   PubMed Web of Science ®Google Scholar
• Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug–drug interactions with rifamycins. Clin Pharmacokinet. 2014;53(6):489–507.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report 2013. World Health Organization; 2013.
   Google Scholar
• Marais B, Zumla A. Advancing global tuberculosis control after the UNGA-HLM. Lancet. 2018;392(10153):1096–1097.
   PubMed Web of Science ®Google Scholar
• Glaziou P, Sismanidis C, Floyd K, Raviglione M. Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med. 2015;5(2):a017798.
   Web of Science ®Google Scholar
• Sudha S. Tuberculosis diagnosis-an overview to the conventional diagnostic methodology and need for nanodiagnosis. Int J Med Eng Inform. 2016;8(1):27–40.
   Google Scholar
• Drancourt M, Carrieri P, Gévaudan M-J, Raoult D. Blood agar and Mycobacterium tuberculosis: the end of a dogma. J Clin Microbiol. 2003;41(4):1710–1711.
   PubMed Web of Science ®Google Scholar
• Parker RA. Implications of tuberculosis sputum culture test sensitivity on accuracy of other diagnostic modalities. Am J Respir Crit Care Med. 2019;199(5):664–664.
   PubMed Web of Science ®Google Scholar
• Pestariati P, Rachmawati M. Solid Media (Lowenstein Jensen) and Liquid Media (Mycobacteria Growth Indicator Tube) Usage Against Mycobacterium tuberculosis Culture in Sputum Suspect Tuberculosis. Health Notions. 2021;5(6):220–224.
   Google Scholar
• Abdelaziz MM, Bakr WM, Hussien SM, Amine AE. Diagnosis of pulmonary tuberculosis using Ziehl–Neelsen stain or cold staining techniques? J Egypt Public Health Assoc. 2016;91(1):39–43.
   PubMedGoogle Scholar
• Lee JE, Kim H-J, Lee SW. The clinical utility of tuberculin skin test and interferon-γ release assay in the diagnosis of active tuberculosis among young adults: a prospective observational study. BMC Infect Dis. 2011;11(1):1–7.
   PubMedGoogle Scholar
• Rose DN, Schechter CB, Adler JJ. Interpretation of the tuberculin skin test. J Gen Intern Med. 1995;10(11):635–642.
   PubMed Web of Science ®Google Scholar
• Trajman A, Steffen R, Menzies D. Interferon-gamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence. Pulm Med. 2013;2013. doi:10.1155/2013/601737
   Google Scholar
• Walsh MC, Camerlin AJ, Miles R, et al. The sensitivity of interferon-gamma release assays is not compromised in tuberculosis patients with diabetes. Int J Tuberc Lung Dis. 2011;15(2):179–184.
   PubMed Web of Science ®Google Scholar
• Nalunjogi J, Mugabe F, Najjingo I, et al. Accuracy and incremental yield of the chest X-Ray in screening for tuberculosis in Uganda: a cross-sectional study. Tuberc Res Treat. 2021;2021. doi:10.1155/2021/6622809
   PubMedGoogle Scholar
• Desikan P, Panwalkar N, Mirza SB, et al. Line probe assay for detection of Mycobacterium tuberculosis complex: an experience from Central India. Indian J Med Res. 2017;145(1):70.
   PubMed Web of Science ®Google Scholar
• Ninan MM, Gowri M, Christopher D, Rupali P, Michael JS. The diagnostic utility of line probe assays for multidrug-resistant tuberculosis. Pathog Glob Health. 2016;110(4–5):194–199.
   PubMed Web of Science ®Google Scholar
• Shaw JA, Irusen EM, Koegelenberg CF. Pleural effusion: tuberculous effusion; 2019.
   Google Scholar
• Laraque F, Griggs A, Slopen M, Munsiff SS. Performance of nucleic acid amplification tests for diagnosis of tuberculosis in a large urban setting. Clin Infect Dis. 2009;49(1):46–54.
   PubMed Web of Science ®Google Scholar
• Phillips M, Cataneo RN, Condos R, et al. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis. 2007;87(1):44–52.
   PubMed Web of Science ®Google Scholar
• Vishinkin R, Busool R, Mansour E, et al. Profiles of volatile biomarkers detect tuberculosis from skin. Adv Sci. 2021;8:2100235.
   Web of Science ®Google Scholar
• World Health Organization. Treatment of Drug-Susceptible Tuberculosis: Rapid Communication. World Health Organization; 2021.
   Google Scholar
• Laurenzi M, Ginsberg A, Spigelman M. Challenges associated with current and future TB treatment. Infect Disord Drug Targets. 2007;7(2):105–119.
   PubMedGoogle Scholar
• Howell M, Wang C, Mahmoud A, Hellermann G, Mohapatra S, Mohapatra S. Dual-function theranostic nanoparticles for drug delivery and medical imaging contrast: perspectives and challenges for use in lung diseases. Drug Deliv Transl Res. 2013;3(4):352–363.
   PubMed Web of Science ®Google Scholar
• Control CfD, Prevention. Treatment for TB disease. US department of Health and Human Services; 2016. Available from https://www.cdc.gov/tb/topic/treatment/tbdisease.htm. Accessed February 16, 2023.
   Google Scholar
• Coelho MRT. Impact of mycobacterial recognition by toll like receptors in the regulation of IL-10 and T helper type of responses; 2012.
   Google Scholar
• Grange JM, Zumla A. The global emergency of tuberculosis: what is the cause? J R Soc Promot Health. 2002;122(2):78–81.
   PubMedGoogle Scholar
• Pym AS, Diacon AH, Tang S-J, et al. Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564–574.
   PubMed Web of Science ®Google Scholar
• Gils T, Lynen L, de Jong BC, Van Deun A, Decroo T. Pretomanid for tuberculosis: a systematic review. Clin Microbiol Infect. 2021;28(1):31–42.
   PubMed Web of Science ®Google Scholar
• Olayanju O, Esmail A, Limberis J, Gina P, Dheda K. Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen. Int J Infect Dis. 2019;85:74–79.
   PubMed Web of Science ®Google Scholar
• Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z. Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharmaceutica Sinica B. 2022;12:3028–3048.
   PubMed Web of Science ®Google Scholar
• Rodrigues AM, Gonçalves SS, de Carvalho JA, Borba-Santos LP, Rozental S, Camargo Z. Current progress on epidemiology, diagnosis, and treatment of sporotrichosis and their future trends. J Fungi. 2022;8(8):776.
   Web of Science ®Google Scholar
• Dye C. Making wider use of the world’s most widely used vaccine: Bacille Calmette–Guérin revaccination reconsidered. J R Soc Interface. 2013;10(87):20130365.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Yasutomi Y. Mycobacterium bovis Bacille Calmette-Guerin as a vaccine vector for global infectious disease control. Tuberc Res Treat. 2011;2011. doi:10.1155/2011/574591
   PubMedGoogle Scholar
• Dockrell HM, Smith SG. What have we learnt about BCG vaccination in the last 20 years? Front Immunol. 2017;8:1134.
   PubMed Web of Science ®Google Scholar
• Jiao X, Lo-Man R, Guermonprez P, et al. Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity. J Immunol. 2002;168(3):1294–1301.
   PubMed Web of Science ®Google Scholar
• Tsuji S, Matsumoto M, Takeuchi O, et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun. 2000;68(12):6883–6890.
   PubMed Web of Science ®Google Scholar
• Azuma I, Ribi EE, Meyer TJ, Zbar B. Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst. 1974;52(1):95–101.
   PubMedGoogle Scholar
• Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R. Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol. 2011;2011. doi:10.1155/2011/405310
   PubMedGoogle Scholar
• Jung S-B, Yang C-S, Lee J-S, et al. The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-activated protein kinase pathway and release of proinflammatory cytokines through toll-like receptors 2 and 4 in human monocytes. Infect Immun. 2006;74(5):2686–2696.
   PubMed Web of Science ®Google Scholar
• Kim K, Sohn H, Kim JS, et al. Mycobacterium tuberculosis Rv0652 stimulates production of tumour necrosis factor and monocytes chemoattractant protein-1 in macrophages through the Toll-like receptor 4 pathway. Immunology. 2012;136(2):231–240.
   PubMed Web of Science ®Google Scholar
• Li J, Fu L, Wang G, Subbian S, Qin C, Zhao A. Unmethylated CpG motif-containing genomic DNA fragment of Bacillus Calmette-Guerin promotes macrophage functions through TLR9-mediated activation of NF-κ B and MAPKs signaling pathways. Innate Immun. 2020;26(3):183–203.
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Yamamoto T, Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis. 1999;52(1):1–11.
   PubMed Web of Science ®Google Scholar
• Gagliardi MC, Teloni R, Giannoni F, et al. Mycobacterium bovis Bacillus Calmette-Guérin infects DC-SIGN–dendritic cell and causes the inhibition of IL-12 and the enhancement of IL-10 production. J Leukoc Biol. 2005;78(1):106–113.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. Tuberculosis Vaccines: Time to Think About the Next Generation. Elsevier; 2013:172–181.
   Google Scholar
• Li J, Zhan L, Qin C. The double-sided effects of Mycobacterium Bovis bacillus Calmette–Guérin vaccine. NPJ Vaccines. 2021;6(1):1–11.
   PubMed Web of Science ®Google Scholar
• Bollampalli VP, Harumi Yamashiro L, Feng X, et al. BCG skin infection triggers IL-1R-MyD88-dependent migration of EpCAMlow CD11bhigh skin dendritic cells to draining lymph node during CD4+ T-cell priming. PLoS Pathog. 2015;11(10):e1005206.
   PubMed Web of Science ®Google Scholar
• Su H, Peng B, Zhang Z, Liu Z, Zhang Z. The Mycobacterium tuberculosis glycoprotein Rv1016c protein inhibits dendritic cell maturation, and impairs Th1/Th17 responses during mycobacteria infection. Mol Immunol. 2019;109:58–70.
   PubMed Web of Science ®Google Scholar
• Bertholet S, Ireton GC, Kahn M, et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol. 2008;181(11):7948–7957.
   PubMed Web of Science ®Google Scholar
• Rossouw M, Nel HJ, Cooke GS, van Helden PD, Hoal EG. Association between tuberculosis and a polymorphic NFκB binding site in the interferon γ gene. Lancet. 2003;361(9372):1871–1872.
   PubMed Web of Science ®Google Scholar
• Hanekom WA. The immune response to BCG vaccination of newborns. Ann N Y Acad Sci. 2005;1062(1):69–78.
   PubMedGoogle Scholar
• Soares AP, Kwong Chung CK, Choice T, et al. Longitudinal changes in CD4+ T-cell memory responses induced by BCG vaccination of newborns. J Infect Dis. 2013;207(7):1084–1094.
   PubMed Web of Science ®Google Scholar
• Dahanayake MH, Jayasundera AC. Nano-based drug delivery optimization for tuberculosis treatment: a review. J Microbiol Methods. 2021;181:106127.
   PubMed Web of Science ®Google Scholar
• Dahanayake MH, Jayasundera AC. Nano-based drug delivery optimization for tuberculosis treatment: a review. J Microbiol Methods. 2020;181:106127.
   PubMed Web of Science ®Google Scholar
• Pham -D-D, Fattal E, Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. Int J Pharm. 2015;478(2):517–529.
   PubMed Web of Science ®Google Scholar
• Ruman U, Fakurazi S, Masarudin MJ, Hussein MZ. Nanocarrier-based therapeutics and theranostics drug delivery systems for next generation of liver cancer nanodrug modalities. Int J Nanomedicine. 2020;15:1437.
   PubMed Web of Science ®Google Scholar
• Pulivendala G, Bale S, Godugu C. Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases. Drug Deliv Transl Res. 2020;10(2):339–353.
   PubMed Web of Science ®Google Scholar
• Dhand C, Prabhakaran MP, Beuerman RW, Lakshminarayanan R, Dwivedi N, Ramakrishna S. Role of size of drug delivery carriers for pulmonary and intravenous administration with emphasis on cancer therapeutics and lung-targeted drug delivery. RSC Adv. 2014;4(62):32673–32689.
   Web of Science ®Google Scholar
• Bhardwaj A, Mehta S, Yadav S, et al. Pulmonary delivery of antitubercular drugs using spray-dried lipid–polymer hybrid nanoparticles. Artif Cells, Nanomed Biotechnol. 2016;44(6):1544–1555.
   PubMed Web of Science ®Google Scholar
• Ahmed R, Aucamp M, Ebrahim N, Samsodien H. Supramolecular assembly of rifampicin and PEGylated PAMAM dendrimer as a novel conjugate for tuberculosis. J Drug Deliv Sci Technol. 2021;66:102773.
   Web of Science ®Google Scholar
• Roy I, Vij N. Nanodelivery in airway diseases: challenges and therapeutic applications. Nanomedicine. 2010;6(2):237–244.
   PubMed Web of Science ®Google Scholar
• Marianecci C, Di Marzio L, Rinaldi F, Carafa M, Alhaique F. Pulmonary delivery: innovative approaches and perspectives. J Biomater Nanobiotechnol. 2011;2(05):567.
   Google Scholar
• Zarogoulidis P, Chatzaki E, Porpodis K, et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine. 2012;7:1551.
   PubMed Web of Science ®Google Scholar
• Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J. Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev. 2009;61(2):115–127.
   PubMed Web of Science ®Google Scholar
• Krombach F, Münzing S, Allmeling A-M, Gerlach JT, Behr J, Dörger M. Cell size of alveolar macrophages: an interspecies comparison. Environ Health Perspect. 1997;105(suppl 5):1261–1263.
   PubMed Web of Science ®Google Scholar
• Ruge CA, Schaefer UF, Herrmann J, et al. The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. PLoS One. 2012;7(7):e40775.
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;5(4):487–495.
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189–207.
   PubMedGoogle Scholar
• Soldati T, Schliwa M. Powering membrane traffic in endocytosis and recycling. Nat Rev Mol Cell Biol. 2006;7(12):897–908.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng. 2006;8:343–375.
   PubMed Web of Science ®Google Scholar
• Formoso P, Muzzalupo R, Tavano L, De Filpo G, Pasquale Nicoletta F. Nanotechnology for the environment and medicine. Mini Rev Med Chem. 2016;16(8):668–675.
   PubMed Web of Science ®Google Scholar
• Cabral H, Nishiyama N, Kataoka K. Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc Chem Res. 2011;44(10):999–1008.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Fessi H, Elaissari A. Theranostic applications of nanoparticles in cancer. Drug Discov Today. 2012;17(17–18):928–934.
   PubMed Web of Science ®Google Scholar
• Funkhouser J. Reinventing pharma: the theranostic revolution. Curr Drug Discov. 2002;2:17–19.
   Web of Science ®Google Scholar
• Wyszogrodzka-Gaweł G, Dorożyński P, Giovagnoli S, et al. An inhalable theranostic system for local tuberculosis treatment containing an isoniazid loaded metal organic framework Fe-MIL-101-NH2—From Raw MOF to drug delivery system. Pharmaceutics. 2019;11(12):687.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wu H, Zhao J, et al. 2D LDH-MoS 2 clay nanosheets: synthesis, catalase-mimic capacity, and imaging-guided tumor photo-therapy. J Nanobiotechnology. 2021;19(1):1–16.
   PubMed Web of Science ®Google Scholar
• Sargazi S, Hajinezhad MR, Rahdar A, et al. CoNi alloy nanoparticles for cancer theranostics: synthesis, physical characterization, in vitro and in vivo studies. Appl Physics A. 2021;127(10):1–12.
   Web of Science ®Google Scholar
• Guo Z, Xie W, Lu J, et al. Ferrous ions doped layered double hydroxide: smart 2D nanotheranostic platform with imaging-guided synergistic chemo/photothermal therapy for breast cancer. Biomaterials Sci. 2021;9(17):5928–5938.
   PubMed Web of Science ®Google Scholar
• Wu J, Williams GR, Zhu Y, et al. Ultrathin chalcogenide nanosheets for photoacoustic imaging-guided synergistic photothermal/gas therapy. Biomaterials. 2021;273:120807.
   PubMed Web of Science ®Google Scholar
• Choi G, Choy JH. Recent progress in layered double hydroxides as a cancer theranostic nanoplatform. Wiley Interdiscip Rev. 2021;13(2):e1679.
   Google Scholar
• Alagarsamy KN, Mathan S, Yan W, et al. Carbon nanomaterials for cardiovascular theranostics: promises and challenges. Bioactive Material. 2021;6(8):2261–2280.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim SY. Gold Nanorod/reduced graphene oxide composite nanocarriers for near-infrared-induced cancer therapy and photoacoustic imaging. ACS Applied Nano Material. 2021;4(11):11849–11860.
   Web of Science ®Google Scholar
• Fahmi MZ, Sholihah NF, Wibrianto A, Sakti SC, Firdaus F, Chang JY. Simple and fast design of folic acid-based carbon dots as theranostic agent and its drug release aspect. Mater Chem Phys. 2021;267:124596.
   Web of Science ®Google Scholar
• Shi J, Zhang H, Wang L, et al. PEI-derivatized fullerene drug delivery using folate as a homing device targeting to tumor. Biomaterials. 2013;34(1):251–261.
   PubMed Web of Science ®Google Scholar
• Tang C, Li H, Hong J, Chai X. Application of nanoparticles in the early diagnosis and treatment of tumors: current status and progress. Tradit Med Res. 2020;5(1):34–43.
   Web of Science ®Google Scholar
• Sumer B, Gao J. Theranostic nanomedicine for cancer; 2008.
   Google Scholar
• Pandey N, Menon JU, Takahashi M, et al. Thermo-responsive fluorescent nanoparticles for multimodal imaging and treatment of cancers. Nanotheranostics. 2020;4(1):1.
   PubMedGoogle Scholar
• Branca RT, Cleveland ZI, Fubara B, et al. Molecular MRI for sensitive and specific detection of lung metastases. Proc Natl Acad Sci. 2010;107(8):3693–3697.
   PubMed Web of Science ®Google Scholar
• Wang H, Zheng L, Peng C, Shen M, Shi X, Zhang G. Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adencarcinoma. Biomaterials. 2013;34(2):470–480.
   PubMed Web of Science ®Google Scholar
• Cho S, Hwang O, Lee I, et al. Chemiluminescent and antioxidant micelles as theranostic agents for hydrogen peroxide associated-inflammatory diseases. Adv Funct Mater. 2012;22(19):4038–4043.
   Web of Science ®Google Scholar
• Banyal S, Malik P, Tuli HS, Mukherjee TK. Advances in nanotechnology for diagnosis and treatment of tuberculosis. Curr Opin Pulm Med. 2013;19(3):289–297.
   PubMed Web of Science ®Google Scholar
• Lee C-N, Wang Y-M, Lai W-F, et al. Super-paramagnetic iron oxide nanoparticles for use in extrapulmonary tuberculosis diagnosis. Clin Microbiol Infect. 2012;18(6):E149–E157.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen H, Zhang S, et al. Structure-property relationships in manganese oxide-mesoporous silica nanoparticles used for T1-weighted MRI and simultaneous anti-cancer drug delivery. Biomaterials. 2012;33(7):2388–2398.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Kong Y, Kundu S, Cirillo JD, Liang H. Antibacterial activities of gold and silver nanoparticles against Escherichia coli and bacillus Calmette-Guérin. J Nanobiotechnology. 2012;10(1):1–9.
   PubMedGoogle Scholar
• Sani A, Cao C, Cui D. Toxicity of gold nanoparticles (AuNPs): a review. Biochem Biophys Rep. 2021;26:100991.
   PubMedGoogle Scholar
• Huang H, Li J, Shi S, et al. Detection of interferon-gamma for latent tuberculosis diagnosis using an immunosensor based on CdS quantum dots coupled to magnetic beads as labels. Int J Electrochem Sci. 2015;10:2580–2593.
   Web of Science ®Google Scholar
• Qi L, Gao X. Emerging application of quantum dots for drug delivery and therapy. Expert Opin Drug Deliv. 2008;5(3):263–267.
   PubMed Web of Science ®Google Scholar
• Wu T, Tang M. Toxicity of quantum dots on respiratory system. Inhal Toxicol. 2014;26(2):128–139.
   PubMed Web of Science ®Google Scholar
• Mohanta D, Patnaik S, Sood S, Das N. Carbon nanotubes: evaluation of toxicity at biointerfaces. J Pharm Anal. 2019;9(5):293–300.
   PubMed Web of Science ®Google Scholar
• Indoria S, Singh V, Hsieh M-F. Recent advances in theranostic polymeric nanoparticles for cancer treatment: a review. Int J Pharm. 2020;582:119314.
   PubMed Web of Science ®Google Scholar
• Mansour HM, Rhee Y-S WX. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;4:299.
   PubMed Web of Science ®Google Scholar
• Kammona O, Kiparissides C. Recent advances in nanocarrier-based mucosal delivery of biomolecules. J Control Release. 2012;161(3):781–794.
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller G. Nanotechnology based drug delivery system (s) for the management of tuberculosis; 2006.
   Google Scholar
• Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263(5153):1600–1603.
   PubMed Web of Science ®Google Scholar
• Zhang L, Pornpattananangkul D, Hu C-M, Huang C-M. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem. 2010;17(6):585–594.
   PubMed Web of Science ®Google Scholar
• Pramanik S, Mohanto S, Manne R, et al. Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases. Mol Pharm. 2021;18(10):3671–3718.
   PubMedGoogle Scholar
• Rai M, Dos Santos CA. Nanotechnology Applied to Pharmaceutical Technology. Springer; 2017.
   Google Scholar
• Kobayashi S, Müllen K. Encyclopedia of Polymeric Nanomaterials. Springer Berlin Heidelberg; 2015.
   Google Scholar
• Bekraki AI. Liposomes-and niosomes-based drug delivery systems for tuberculosis treatment. In: Nanotechnology Based Approaches for Tuberculosis Treatment. Elsevier; 2020:107–122.
   Google Scholar
• Yusefi M, Chan H-Y, Teow S-Y, et al. 5-fluorouracil encapsulated chitosan-cellulose fiber bionanocomposites: synthesis, characterization and in vitro analysis towards colorectal cancer cells. Nanomaterials. 2021;11(7):1691.
   Web of Science ®Google Scholar
• Ahmad A, Ahmad I, Khan A, Abdullah M, Chee CY, Verpoort F. Introduction to nanomedicine an overview. Nanomed Manufactu Appli. 2021;1–20. doi:10.1016/B978-0-12-820773-4.00001-9
   Google Scholar
• Debnath SK, Srivastava R. Drug delivery with carbon-based nanomaterials as versatile nanocarriers: progress and prospects. Front Nanotechnol. 2021;3:15.
   Google Scholar
• Souto EB. Patenting Nanomedicines: Legal Aspects, Intellectual Property and Grant Opportunities. Springer Science & Business Media; 2012.
   Google Scholar
• Vijayaraj Kumar P, Agashe H, Dutta T, Jain NK. PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug. Curr Drug Deliv. 2007;4(1):11–19.
   PubMedGoogle Scholar
• Frijlink H, De Boer A. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2004;1(1):67–86.
   PubMedGoogle Scholar
• Machelart A, Salzano G, Li X, et al. Intrinsic antibacterial activity of nanoparticles made of β-cyclodextrins potentiates their effect as drug nanocarriers against tuberculosis. ACS Nano. 2019;13(4):3992–4007.
   PubMed Web of Science ®Google Scholar
• Rahimpour Y, Hamishehkar H, Nokhodchi A. Lipidic Micro-and Nano-Carriers for pulmonary drug delivery–a state-of-the-art review. Pulm Drug Deliv. 2015;123–142. doi:10.1002/9781118799536.ch6
   Google Scholar
• Jafari A, Mosavari N, Movahedzadeh F, et al. Bactericidal impact of Ag, ZnO and mixed AgZnO colloidal nanoparticles on H37Rv Mycobacterium tuberculosis phagocytized by THP-1 cell lines. Microb Pathog. 2017;110:335–344.
   PubMed Web of Science ®Google Scholar
• Ivask A, ElBadawy A, Kaweeteerawat C, et al. Toxicity mechanisms in Escherichia coli vary for silver nanoparticles and differ from ionic silver. ACS Nano. 2014;8(1):374–386.
   PubMed Web of Science ®Google Scholar
• Jafari A, Kharazi S, Mosavari N, et al. Synthesis of mixed metal oxides nano-colloidal particles and investigation of the cytotoxicity effects on the human pulmonary cell lines: a prospective approach in anti-tuberculosis inhaled nanoparticles. Orient J Chem. 2017;33(3):1529.
   Google Scholar
• Martínez-Carmona M, Gun’Ko Y, Vallet-Regí M. ZnO nanostructures for drug delivery and theranostic applications. Nanomaterials. 2018;8(4):268.
   Web of Science ®Google Scholar
• Saifullah B, Chrzastek A, Maitra A, et al. Novel anti-tuberculosis nanodelivery formulation of ethambutol with graphene oxide. Molecules. 2017;22(10):1560.
   PubMed Web of Science ®Google Scholar
• Rawal T, Patel S, Butani S. Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline. Eur J Pharm Sci. 2018;124:273–287.
   PubMed Web of Science ®Google Scholar
• Prabhu P, Fernandes T, Chaubey P, et al. Mannose-conjugated chitosan nanoparticles for delivery of rifampicin to osteoarticular tuberculosis. Drug Deliv Transl Res. 2021;11(4):1509–1519.
   PubMed Web of Science ®Google Scholar
• Öztürk AA, Yenilmez E, Özarda MG. Clarithromycin-loaded poly (lactic-co-glycolic acid)(PLGA) nanoparticles for oral administration: effect of polymer molecular weight and surface modification with chitosan on formulation, nanoparticle characterization and antibacterial effects. Polymers. 2019;11(10):1632.
   PubMed Web of Science ®Google Scholar
• Nemati E, Mokhtarzadeh A, Panahi-Azar V, et al. Ethambutol-loaded solid lipid nanoparticles as dry powder inhalable formulation for tuberculosis therapy. AAPS PharmSciTech. 2019;20(3):1–9.
   Web of Science ®Google Scholar
• Ali HR, Ali MR, Wu Y, et al. Gold nanorods as drug delivery vehicles for rifampicin greatly improve the efficacy of combating Mycobacterium tuberculosis with good biocompatibility with the host cells. Bioconjug Chem. 2016;27(10):2486–2492.
   PubMed Web of Science ®Google Scholar
• Varma JR, Kumar TS, Prasanthi B, Ratna JV. Formulation and characterization of pyrazinamide polymeric nanoparticles for pulmonary tuberculosis: efficiency for alveolar macrophage targeting. Indian J Pharm Sci. 2015;77(3):258.
   PubMed Web of Science ®Google Scholar
• Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG. Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm. 2007;67(3):655–666.
   PubMed Web of Science ®Google Scholar
• Vishwa B, Moin A, Gowda D, et al. Pulmonary Targeting of inhalable moxifloxacin microspheres for effective management of tuberculosis. Pharmaceutics. 2021;13(1):79.
   PubMed Web of Science ®Google Scholar
• Xia X, Pethe K, Kim R, et al. Encapsulation of anti-tuberculosis drugs within mesoporous silica and intracellular antibacterial activities. Nanomaterials. 2014;4(3):813–826.
   Web of Science ®Google Scholar
• Zomorodbakhsh S, Abbasian Y, Naghinejad M, Sheikhpour M. The effects study of isoniazid conjugated multi-wall carbon nanotubes nanofluid on Mycobacterium tuberculosis. Int J Nanomedicine. 2020;15:5901.
   PubMed Web of Science ®Google Scholar
• El-Ridy MS, Yehia SA, Kassem MA, Mostafa DM, Nasr EA, Asfour MH. Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety. Drug Deliv. 2015;22(1):21–36.
   PubMed Web of Science ®Google Scholar
• Ahmed RM. Development of Rifampicin Loaded in Surface-Modified 4.0 G PAMAM Dendrimer as a Novel Antituberculosis Pulmonary Drug Delivery System. Elsevier; 2020.
   Google Scholar
• Garcia-Contreras L, Sung JC, Muttil P, et al. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother. 2010;54(4):1436–1442.
   PubMed Web of Science ®Google Scholar
• Basha RY, Doble M. Dual delivery of tuberculosis drugs via cyclodextrin conjugated curdlan nanoparticles to infected macrophages. Carbohydr Polym. 2019;218:53–62.
   PubMed Web of Science ®Google Scholar
• Henostroza MAB, Melo KJC, Yukuyama MN, Löbenberg R, Bou-Chacra NA. Cationic rifampicin nanoemulsion for the treatment of ocular tuberculosis. Colloids Surfaces A. 2020;597:124755.
   Google Scholar
• Peters K, Leitzke S, Diederichs J, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother. 2000;45(1):77–83.
   PubMed Web of Science ®Google Scholar
• Goyal S, Klassert TE, Slevogt H. C-type lectin receptors in tuberculosis: what we know. Med Microbiol Immunol. 2016;205(6):513–535.
   PubMed Web of Science ®Google Scholar
• Ragas A, Roussel L, Puzo G, Riviere M. The Mycobacterium tuberculosis cell-surface glycoprotein apa as a potential adhesin to colonize target cells via the innate immune system pulmonary C-type lectin surfactant protein A. J Biol Chem. 2007;282(8):5133–5142.
   PubMed Web of Science ®Google Scholar
• Minnikin DE. Complex lipids, their chemistry biosynthesis and roles. Bio Mycobacteria. 1982;1:95–184.
   Google Scholar
• Lemmer Y, Kalombo L, Pietersen R-D, et al. Mycolic acids, a promising mycobacterial ligand for targeting of nanoencapsulated drugs in tuberculosis. J Control Release. 2015;211:94–104.
   PubMed Web of Science ®Google Scholar
• Vieira AC, Chaves LL, Pinheiro M, et al. Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages. Artif Cells, Nanomed Biotechnol. 2018;46(sup1):653–663.
   PubMed Web of Science ®Google Scholar
• Mukhtar M, Csaba N, Robla S, et al. Dry powder comprised of isoniazid-loaded nanoparticles of hyaluronic acid in conjugation with mannose-anchored chitosan for macrophage-targeted pulmonary administration in tuberculosis. Pharmaceutics. 2022;14(8):1543.
   PubMed Web of Science ®Google Scholar
• Bhardwaj A, Kumar L, Narang R, Murthy R. Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis. Artif Cells Nanomed Biotechnol. 2013;41(1):52–59.
   PubMed Web of Science ®Google Scholar
• Goyal AK, Garg T, Rath G, Gupta UD, Gupta P. Development and characterization of nanoembedded microparticles for pulmonary delivery of antitubercular drugs against experimental tuberculosis. Mol Pharm. 2015;12(11):3839–3850.
   PubMed Web of Science ®Google Scholar
• Grenha A, Alves AD, Guerreiro F, et al. Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: therapeutic assessment in a murine model of tuberculosis infection. Eur J Pharm Biopharm. 2020;147:38–44.
   PubMed Web of Science ®Google Scholar